$EPIX
ESSA Pharma Inc.

2023 Q4 Form 10-K Financial Statement

#000155837023019732 Filed on December 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $62.77K
YoY Change -23.91%
Gross Profit $0.00 -$62.77K
YoY Change -23.91%
Gross Profit Margin
Selling, General & Admin $2.218M $2.086M $11.37M
YoY Change -14.21% -24.74% -9.44%
% of Gross Profit
Research & Development $5.377M $5.226M $21.32M
YoY Change 0.61% 20.1% -12.67%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.595M $7.150M $32.14M
YoY Change -3.45% 0.36% -13.07%
Operating Profit -$7.150M -$32.20M
YoY Change 0.36% -13.09%
Interest Expense $1.630M $1.668M $5.560M
YoY Change 45.07% 127.37% 216.16%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.964M -$5.481M -$26.58M
YoY Change -11.53% -14.22% -24.52%
Income Tax $0.00 $1.600K
% Of Pretax Income
Net Earnings -$5.964M -$5.481M -$26.58M
YoY Change -11.53% -13.32% -24.27%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.60
Diluted Earnings Per Share -$0.14 -$0.12 -$0.60
COMMON SHARES
Basic Shares Outstanding 44.14M 44.10M 44.09M
Diluted Shares Outstanding 44.13M 44.09M

Balance Sheet

Concept 2023 Q4 2023 Q3 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.1M $148.1M $148.1M
YoY Change -12.85% -11.46% -11.46%
Cash & Equivalents $35.34M $33.70M $33.70M
Short-Term Investments $106.8M $114.4M $114.4M
Other Short-Term Assets $1.568M $585.4K $585.4K
YoY Change 4.45% -67.76% -67.76%
Inventory
Prepaid Expenses $1.568M $585.4K
Receivables $180.6K $135.1K $135.1K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $143.9M $148.8M $148.8M
YoY Change -12.59% -11.99% -11.99%
LONG-TERM ASSETS
Property, Plant & Equipment $363.2K $68.01K $68.01K
YoY Change 132.71% -63.53% -63.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $257.2K $257.2K $257.2K
YoY Change -0.85% -0.85% -0.85%
Total Long-Term Assets $620.4K $325.3K $325.3K
YoY Change 49.31% -27.07% -27.07%
TOTAL ASSETS
Total Short-Term Assets $143.9M $148.8M $148.8M
Total Long-Term Assets $620.4K $325.3K $325.3K
Total Assets $144.5M $149.1M $149.1M
YoY Change -12.43% -12.03% -12.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $2.028M $2.028M
YoY Change 58.99% 112.47% 112.47%
Accrued Expenses $284.8K $845.7K $1.467M
YoY Change -61.43% 4.74% 8.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.531M $3.495M $3.495M
YoY Change 20.3% 51.28% 51.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $275.5K $0.00 $0.00
YoY Change 470.64% -100.0% -100.0%
Total Long-Term Liabilities $275.5K $0.00 $0.00
YoY Change 470.64% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.531M $3.495M $3.495M
Total Long-Term Liabilities $275.5K $0.00 $0.00
Total Liabilities $3.806M $3.495M $3.495M
YoY Change 27.58% 46.43% 46.43%
SHAREHOLDERS EQUITY
Retained Earnings -$185.4M -$179.5M
YoY Change 16.17% 17.39%
Common Stock $278.5M $278.2M
YoY Change 0.13% 0.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $140.7M $145.6M $145.6M
YoY Change
Total Liabilities & Shareholders Equity $144.5M $149.1M $149.1M
YoY Change -12.43% -12.03% -12.03%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023
OPERATING ACTIVITIES
Net Income -$5.964M -$5.481M -$26.58M
YoY Change -11.53% -13.32% -24.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.787M -$4.492M -$19.78M
YoY Change 35.88% -42.82% -31.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.233M -$267.2K -$3.527M
YoY Change -1039.42% -91.0% -93.26%
Cash From Investing Activities $8.233M -$267.2K -$3.527M
YoY Change -1039.42% -91.0% -93.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 196.7K -18.16K -68.16K
YoY Change 1156.45% -47.56% -126.97%
NET CHANGE
Cash From Operating Activities -6.787M -4.492M -19.78M
Cash From Investing Activities 8.233M -267.2K -3.527M
Cash From Financing Activities 196.7K -18.16K -68.16K
Net Change In Cash 1.643M -4.777M -23.37M
YoY Change -128.05% -56.01% -71.05%
FREE CASH FLOW
Cash From Operating Activities -$6.787M -$4.492M -$19.78M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44089557
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44038241
CY2023Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-111821
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001633932
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#ShortTermInvestments
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#ShortTermInvestments
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44073076
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44100838
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37410
CY2023 dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
CY2023 dei Entity Address Country
EntityAddressCountry
CA
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1250703
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
CY2023 dei City Area Code
CityAreaCode
778
CY2023 dei Local Phone Number
LocalPhoneNumber
331-0962
CY2023 dei Security12b Title
Security12bTitle
Common Shares
CY2023 dei Trading Symbol
TradingSymbol
EPIX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 epix Document Financial Statement Error Correction Flag
DocumentFinancialStatementErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Public Float
EntityPublicFloat
78800000
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44142088
CY2023 dei Auditor Firm
AuditorFirmId
731
CY2023 dei Auditor Name
AuditorName
DAVIDSON & COMPANY LLP
CY2023 dei Auditor Location
AuditorLocation
Vancouver, Canada
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33701912
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57076475
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
114374489
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
110161029
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
135057
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
6211
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
585420
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1815626
CY2023Q3 us-gaap Assets Current
AssetsCurrent
148796878
CY2022Q3 us-gaap Assets Current
AssetsCurrent
169059341
CY2023Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
257245
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
259455
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68008
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186499
CY2023Q3 us-gaap Assets
Assets
149122131
CY2022Q3 us-gaap Assets
Assets
169505295
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3414743
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2176565
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80328
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
133834
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3495071
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2310399
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76418
CY2023Q3 us-gaap Liabilities
Liabilities
3495071
CY2022Q3 us-gaap Liabilities
Liabilities
2386817
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44100838
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44073076
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
278161537
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
278089136
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49047280
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44043503
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2120398
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2135145
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179461359
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152879016
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
145627060
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149122131
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169505295
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21322530
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24415246
CY2023 epix Financing Costs
FinancingCosts
6942
CY2022 epix Financing Costs
FinancingCosts
13746
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10811574
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12544760
CY2023 us-gaap Operating Expenses
OperatingExpenses
32141046
CY2022 us-gaap Operating Expenses
OperatingExpenses
36973752
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6529
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1687
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
5553774
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
1736641
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26580743
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35215072
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-111821
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-26582343
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35103251
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14747
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-58666
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26567596
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35161917
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44089557
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44038241
CY2023 us-gaap Profit Loss
ProfitLoss
-26582343
CY2022 us-gaap Profit Loss
ProfitLoss
-35103251
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
118491
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
121787
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
671268
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-69653
CY2023 us-gaap Accretion Expense
AccretionExpense
6942
CY2022 us-gaap Accretion Expense
AccretionExpense
13305
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20352
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
-374
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
189213
CY2023 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
528
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-845
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
5007469
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7888085
CY2023 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
128846
CY2022 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-482801
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1232416
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-366256
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1235577
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1629065
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19781716
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27999149
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
365203691
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
296012498
CY2023 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
361676542
CY2022 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
242959084
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3527149
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53053414
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
319832
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
68709
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
66926
CY2023 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
136866
CY2022 epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
134023
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-68157
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
252735
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2459
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51279
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23374563
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-80748549
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57076475
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137825024
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33701912
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57076475
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
194005552
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
319832
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
66926
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7888085
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35161917
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
167118478
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
68709
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5007469
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26567596
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
145627060
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ESSA Pharma Inc. (the “Company”) was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5. The registered and records office address is Suite 3500, The Stack, 1133 Melville Street, Vancouver, British Columbia, V6E 4E5. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has a license to certain patents (the “NTD Technology”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As at September 30, 2023, no products are in commercial production or use.</p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and income taxes. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions that have been made, relate to the following key estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. Changes in facts and circumstances as a result of income tax audits, reassessments, changes to corporate structure and associated domiciling, jurisprudence and any new legislation may result in an increase or decrease the provision for income taxes. The value of deferred tax assets is evaluated based on the probability of realization; the Company has assessed that it is improbable that such assets will be realized and has accordingly not recognized a value for deferred taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Share-based payments and compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has applied estimates with respect to the valuation of shares issued for non-cash consideration. Shares are valued at the fair value of the equity instruments granted at the date the Company receives the goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the fair value of the underlying Common Shares, the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are discussed in Note 9.</p>
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.55
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2176565
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72910
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.41
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Change in presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended September 30, 2023, the Company identified a presentation item that required adjustments to be recorded in the historical consolidated statements of cash flows to conform to the presentation required under U.S. GAAP. Interest from short-term investments of $705,020 for the year ended September 30, 2022 has been reclassified from investing activities to operating activities. There were no changes to net loss of the Company or <span style="-sec-ix-hidden:Hidden_ilqp4H9x3UeeSj7zg-kL4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">earnings</span></span> per <span style="-sec-ix-hidden:Hidden_uPwaofhXOUatr_NRDuquTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share</span></span> in the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes this reclassification and presentation change in the historical consolidated statement of cash flow for the year ended September 30, 2022 is not material and has reflected this reclassification and presentation change in the comparative period included within these consolidated financial statements.</p>
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
113943845
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
43248
CY2023Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
473892
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114374489
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
109833757
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58666
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
385938
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110161029
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
114400000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110200000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
43248
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58666
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
24839
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1611516
CY2023Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2022Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
181835
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
378746
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
22275
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
585420
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1815626
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2028265
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
954598
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
845730
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
807484
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
540748
CY2022Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
414483
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3414743
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
308286
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
121787
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
186499
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
118491
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68008
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
330970
CY2022 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
13305
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
134023
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
210252
CY2023 epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
6942
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
136866
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
80328
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80328
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.050
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1347500
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
175759
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.60
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7902061
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.97
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
89287
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.27
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8112774
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.97
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6444885
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.79
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8112774
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M4D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
300000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1347500
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.20
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3234750
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.84
CY2023 epix Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
307273
CY2023 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExpired
-49.86
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2927477
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.11
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2927477
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.270
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.270
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26580743
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35215072
CY2023 epix Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
7177000
CY2022 epix Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
9509000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
643000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
963000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-4000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-25000
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1212000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1288000
CY2023 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
325000
CY2022 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
165000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5003000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7007000
CY2023Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43726000
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37710000
CY2023Q3 epix Deferred Tax Assets Equipment And Intangible Assets
DeferredTaxAssetsEquipmentAndIntangibleAssets
77000
CY2022Q3 epix Deferred Tax Assets Equipment And Intangible Assets
DeferredTaxAssetsEquipmentAndIntangibleAssets
77000
CY2023Q3 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
29000
CY2022Q3 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
29000
CY2023Q3 epix Deferred Tax Assets Financing Costs
DeferredTaxAssetsFinancingCosts
1191000
CY2022Q3 epix Deferred Tax Assets Financing Costs
DeferredTaxAssetsFinancingCosts
2026000
CY2023Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
210000
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
210000
CY2023Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-54000
CY2022Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
125000
CY2023Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
45179000
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40177000
CY2023Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45179000
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40177000
CY2023Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 epix Cash Canada Deposit Insurance Corporation Insured Amount
CashCanadaDepositInsuranceCorporationInsuredAmount
100000
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2023Q3 epix Working Capital
WorkingCapital
145301807

Files In Submission

Name View Source Status
0001558370-23-019732-index-headers.html Edgar Link pending
0001558370-23-019732-index.html Edgar Link pending
0001558370-23-019732.txt Edgar Link pending
0001558370-23-019732-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230930.xsd Edgar Link pending
tmb-20230930x10k.htm Edgar Link pending
tmb-20230930x10k002.jpg Edgar Link pending
tmb-20230930x10k003.jpg Edgar Link pending
tmb-20230930x10k004.jpg Edgar Link pending
tmb-20230930x10k005.jpg Edgar Link pending
tmb-20230930xex10d3.htm Edgar Link pending
tmb-20230930xex21d1.htm Edgar Link pending
tmb-20230930xex23d1.htm Edgar Link pending
tmb-20230930xex23d1001.jpg Edgar Link pending
tmb-20230930xex23d1002.jpg Edgar Link pending
tmb-20230930xex31d1.htm Edgar Link pending
tmb-20230930xex31d2.htm Edgar Link pending
tmb-20230930xex32d1.htm Edgar Link pending
tmb-20230930xex4d2.htm Edgar Link pending
tmb-20230930xex97.htm Edgar Link pending
tmb-20230930_cal.xml Edgar Link unprocessable
tmb-20230930_lab.xml Edgar Link unprocessable
tmb-20230930_def.xml Edgar Link unprocessable
tmb-20230930_pre.xml Edgar Link unprocessable
tmb-20230930x10k_htm.xml Edgar Link completed